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Abstract
Scientists employing methods of genetic engineering have developed a new group of living organisms, termed ‘modified 
organisms’, which found application in, among others, medicine, the pharmaceutical industry and food distribution. 
The introduction of transgenic products to the food market resulted in them becoming a controversial topic, with their 
proponents and contestants. The presented study aims to systematize objective data on the potential benefits and risks 
resulting from the consumption of transgenic food. Genetic modifications of plants and animals are justified by the 
potential for improvement of the food situation worldwide, an increase in yield crops, an increase in the nutritional value 
of food, and the development of pharmaceutical preparations of proven clinical significance. In the opinions of critics, 
however, transgenic food may unfavourably affect the health of consumers. Therefore, particular attention was devoted 
to the short- and long-lasting undesirable effects, such as alimentary allergies, synthesis of toxic agents or resistance to 
antibiotics. Examples arguing for the justified character of genetic modifications and cases proving that their use can be 
dangerous are innumerable. In view of the presented facts, however, complex studies are indispensable which, in a reliable 
way, evaluate effects linked to the consumption of food produced with the application of genetic engineering techniques. 
Whether one backs up or negates transgenic products, the choice between traditional and non-conventional food remains 
to be decided exclusively by the consumers.
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INTRODUCTION
In parallel with an intense development of genetic engineering 
techniques and altering the needs of contemporary economy 
an increased interest is devoted to food products obtained 
using transgenesis processes. The new type of food, termed 
genetically modified or transgenic food,1 permitted the 
commercialization of crops, allowed in parallel to avoid 
restrictions linked to traditional cultivation. In line with 
Regulation 1829/2003 of the European Parliament the term 
of ‘genetically modified food’ denotes food which itself is a 
GMO2 or ‘food containing or composed of a GMO, or food 
produced using GMO’ [1, 2, 3].
The origins of plant and animal modification date back 
to the 1970s. In 1973, Stanley Cohen and Herbert Boyer 
obtained for the first time recombined DNA, starting the era 
of genetic engineering. The pioneer plants subjected to the 
process of transgenesis involved tobacco and petunia, but a 
real success proved to be introduction to the market in 1994 
of a modified FlavrSavr tomato plant, which forecasted the 
commercialization of transgenesis products. The assortment 
of genetically modified food includes first of all plants, and 
much narrower range of animals and microbes. The most 
frequently transformed plants include soybean, maize and 
rape. Moreover, potatoes, tomatoes, cotton and tobacco used to 
be subjected to the process of transgenesis, and among animals, 
1. In this study, the terms ‘transgenic food’ or ‘GM food’ will be used 
instead of ‘genetically modified food’.
2. GMO – genetically modified organism.
species such as cattle and pigs. The genetic modifications aim 
at improving utilizable and technological traits, nutritional 
enrichment of the obtained products, as well as providing 
potential for the synthesis of therapeutic substances using 
transgenic organisms [3, 4, 5, 6, 7, 8]. The introduction of 
genetically modified components for general use is linked 
to the obligation of their appropriate labelling, in line with 
European Union (UE) law. The labelling imperative pertains to 
all trade goods which contain GM components and products 
produced with use of GMO, in which the contents of transgenic 
components exceeds 0.9%. Detection of GM components 
becomes an inseparable element of legislative procedure and 
the introduction to the market of genetically modified food, 
ensuring, in parallel, appropriate labelling of products, subject 
to respective official control [2, 3, 9, 10, 11, 12].
The procedure of certification genetically modified food is 
controlled by a number of legal acts and requirements, the 
fulfilling of which provides conditions for allowing GMO 
to enter trade turnover. Not only the traits of the parental 
organism, source and expression products of genes used 
for modification are evaluated, but also new, non-existing 
earlier properties of the transgenic organism. The analysis 
includes effects of GMO on living bodies, the environment and 
biodiversity, with particular attention paid to the risks of using 
a GMO. In European Union countries, genetically modified 
food is required to fulfil respective legal Acts, among them 
Directive 1829/2003/WE on genetically modified food and 
fodder, and Directive 1830/2003/WE, related with the potential 
for monitoring and labelling genetically modified organisms, 
while in the individual Member States the appropriate legal 
and normative Acts. It should be added that the procedure 
for obtaining consent for the legalization of GMO is complex 
and includes acceptance of consecutive supervising bodies, 
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both at the European level, first of all of the European Food 
Safety Authority (EFSA), and at the national level [3, 13, 14].
The process of introducing genetically modified food to 
consumer markets is preceded by a detailed technological 
and toxicological analysis, aimed at evaluation of safety 
linked to its use. A number of methods are distinguished 
which allow to evaluate the precisely GMO content in a 
studied sample. Molecular biology techniques are based, 
first of all, on analysis of nucleotide sequence in the chain of 
genetic information, protein analysis, or on physicochemical 
reactions. The need for monitoring products containing 
components with modified genetic information promoted 
development of networks of laboratories, including, among 
others, the European Network of GMO Laboratories 
(ENGL), formed on the grounds of European Union law, 
the principal purpose of which involves the development of 
standards in sampling, detection and quantitative analysis 
of genetic material contained in a studied sample. Beyond 
doubt, genetically modified food products allowed to enter 
worldwide trade are scrupulously tested for potential effects 
resulting from their consumption [2, 3, 15].
Compared with global producers of transgenic food (such 
as the United States, Argentina, Brazil, India, Canada or 
China), the countries of United Europe manifest a slower 
increase in the assortment of food originating from genetic 
modifications, which reflects the principle of restricted 
confidence to products of genetic engineering. Therefore, a 
proportion of EU member States strive to eliminate GMO. 
Nevertheless, the European countries which in agriculture 
take advantage of transgenesis products include Poland, 
due to the fact that territory of this country still continues 
to be free of the rigorous orders making it a GMO-free zone, 
although, in accordance with superiority of the European law, 
Poland cannot block trade involving GM products placed 
in the EU market and permitted to enter trade turnover by 
decision of the European Commission. It should be mentioned 
that legal rules related to cultivation and trade involving 
transgenic food in Poland and countries of the UE continue 
to undergo dynamic alterations [5, 6, 7, 8, 16, 17].
Problems associated with biotechnology, including 
genetically modified food, represent a very current topic, 
evoking several inverse feelings in scientific circles and in 
society [1, 7, 18]. The principal investigative problem involves 
the effect of genetically modified alimentation on the human 
body. The study aims at presenting objective data on the 
advantages and disadvantages of GM food, the potential 
for taking advantage of such food, reliable benefits and risks 
linked to it.
Benefits resulting from genetic modification of food 
products.  The increasing number of transgenic food 
products on the food market induces the belief that genetic 
modification of plants and animals provides profits. The 
potential for improvement of agronomic, technological or 
utilitarian traits prompts food producers to an increasingly 
frequent use of achievements provided by genetic engineering. 
The groundwork of every modification performed involves a 
complex procedure of altering genome structure which, in 
effect, is responsible for the expression and manifestation of 
the desired utilitarian trait [19, 20, 21, 22].
Modification of chemical composition in transgenic 
food. Among numerous modifications induced in plants, 
transformations resulting in altered chemical composition 
of food products deserve particular attention. Enrichment 
of transgenic food in specific alimentary products results 
in such food frequently having a much higher utility value 
than traditional food products. Moreover, it provides a 
concentrated source of nutraceutics, or substances carrying 
high therapeutic and pro-health value, representing a 
desirable element of a differentiated diet. The group of 
nutraceutics contains, first of all, vitamins A, C, E, plant 
pigments, indispensable unsaturated fatty acids (IUFA), 
alimentary cellulose, and pre- and probiotics [20].
The achievements of genetic engineering include the 
significant example of Golden Rice, the genome of which 
was modified by the introduction of additional copies of 
genes conditioning the synthesis of provitamin A (Tab. 1). 
Carotenoids, including, among other, β-carotene, vitamin A 
and its provitamin, represent a group of biologically active 
compounds responsible for normal sight and body resistance [9, 
18, 23]. The project of enriching rice in food products involved 
the isolation and transfer of genes from Erwinia uredovora 
bacteria and jonquil flowers directly to rice grains. A change 
in expression of individual alleles resulted in an increased 
activity of the enzyme of phytoene synthase, translated to 
an increased amount of synthesized β-carotene. The success 
of the project was followed by subsequent modifications, 
achieving parallel augmentation of the level and bioavailability 
of iron. In this way, Golden Rice proved to provide the product 
of choice for the reduction of malnutrition, due to its high 
nutritive value and low price [22, 24, 25].
Using the techniques for the biotechnological improvement 
of plants, other modifications of traits were conducted in 
transgenic food, targeted at the altered content of specific 
proteins, lipids and carbohydrates. The mentioned food 
components, manifesting suitability for the process of genetic 
transformation, permitted the development of desirable 
quality traits, with parallel improvement of nutritive value 
in individual products of transgenesis. In particular, an 
altered profile of amino acids, lysine, methionine, cysteine 
and tryptophan caused plant varieties of – until now – low 
value to possibly become a source of exogenous protein. This 
can be exemplified by cultures of sweet lupine, enriched with 
additional molecules of methionine [19, 26].
Genetic modifications were also prompted by the desire to 
improve the structure of alimentary lipids. An increasing share 
of saturated fatty acids, paralleled by a decreasing consumption 
of mono- and polyunsaturated fatty acids, prompted scientists 
to transform the natural composition of oil plants. Laboratory 
investigations resulted in soybean varieties with a few-fold 
increased content of oleinic (oleic) acid – a monounsaturated 
fatty acid – and varieties of rape rich in stearic acid – a 
saturated fatty acid free of unfavorable effects for health. The 
introduction to plant cells of genes responsible for synthesis 
of unsaturated fatty acids promoted also the alternative 
production of omega-3 acids (polyunsaturated fatty acids), 
highly valued for their pro-health properties, e.g. for reduction 
of LDL-cholesterol and triglyceride levels in serum and for 
reduction of cardiovascular diseases risk. This group of plants 
includes rape, the principal object of studies in this branch 
of transgenesis [7, 19, 27].
New nutritional values in transgenesis products were 
obtained also due to changes in the composition of 
carbohydrates. An interesting example of such a process 
involves the genetically modified potato variety, Amflora. The 
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bulk of potato bulb-contained polysaccharides is formed by 
starch, consisting of two elements, amylose and amylopectine. 
While in the processing industry amylose represents a useless 
element, amylopectine is widely used in the production of 
starch, paper, and in the processing of textiles. The synthesis 
of starch requires various enzymes, which include granule 
bound starch synthase (GSBB), the primary function of 
which involves the production of amylose. In the absence 
of GSBB, amylopectin is produced exclusively. The above 
information permitted the working out of a modification 
allowing alteration of the composition of potato starch. The 
transgenesis process involved the introduction to potato 
bulbs of an additional copy of the GSBB-coding gene. The 
transferred and recipient genome-integrated genetic material, 
acting by co-suppression or gene silencing, produced the 
effect of decreasing synthesis of the enzyme, and in this way 
promoting the production of amyloseless starch. Although 
the Amflora potato was permitted to be grown in European 
countries exclusively for industrial purposes, nevertheless 
it induced a widespread protest from society [17, 28, 29, 
30, 31]. The application of techniques aimed at improving 
plant composition due to their content of specific alimentary 
components and an increased nutritional value, represents 
an increasingly broad branch in food technology.
Improvement in technological and utility trends. The 
aim of plant cell genetic transformation involves not only 
modification of the chemical composition and nutritional 
value of transgenic products, but also alterations in functional 
traits, important in the technological and processing processes. 
The highest interest is attracted by varieties in which the 
introduced change manifests certain practical importance. 
One of the first achievements in perfecting food on the 
molecular level involved the above-mentioned FlavrSavr 
tomato, the genetic material of which was transformed with 
respect to activity of the enzyme of polygalacturonase. A 
reaction of silencing gene expression, responsible for the 
phenomenon of ripening, resulted in the tomato manifesting 
a slowed-down metabolism at the stage when the process 
progressed rapidly and, due to the slowing, it gained longevity, 
permitting its long storage (Tab. 1) [7, 16, 19, 24, 32].
Potato bulbs, because they are easily modified, became 
important objects of studies. Their transformation included 
not only their quantitative composition but, first of all, their 
technological parameters. The most important alterations 
included decrease in the amount of reducing sugars, 
paralleled by an increased content of cyclodextrins, change 
in the activity of polyphenol oxidase responsible for the 
phenomenon of potato darkening, and a reduced content of 
alkaloids which negatively affect the process of potato storage. 
A potato was successfully cultivated in which the Bt gene, 
isolated from Bacillus thuringiensis bacteria, conditioning 
resistance to potato beetle, allowed an increase in the potato 
crop (Tab. 1) [28, 33]. The same resistance gene was used for 
the transgenesis of maize. It is assumed that a toxin coded by 
a bacterial chromosome, after transferring to plant tissues, 
allows the development of resistance to noxious insects 
which reduce crops, but exert no negative influence on the 
health of humans and animals consuming the plants. Due 
to such procedures, the maize became resistant to corn borer 
(Pyrausta mirilabilis), while its commercial variety (MON810) 
was admitted to cultivation worldwide, including Poland and 
other countries of the European Union [17, 24, 29, 33, 34, 35].
Another type of component in genetically modified food 
involves products from the transgenesis of animal products. 
The rationale for altering the structure of the genes includes 
attempts to improve utility traits of farm animals and 
attainment of the highest economical profits. Farm animal 
modifications encompass several branches of contemporary 
economy, including agriculture, the food industry, pharmacy 
and medicine. The principal objects in studies on transgenesis 
processes include cattle and pigs, while the main directions 
of transformation involve optimization of their alimentary 
potential and parameters of breeding. Modification of genetic 
material aimed at enrichment of its fraction responsible for 
synthesis of growth hormone resulted in the production 
of animals manifesting a higher growth rate and greater 
increases in body weight. At present, attempts are being made 
to obtain varieties of the animals with low feed demand, 
compared to their rate of growth. Such attempts have been 
successful in the production of transgenic fish, such as carp, 
trout and salmon [7, 24, 36]. Extensive interest was devoted 
to improvement of the nutritive value of milk originating 
from genetically modified cows, goats and sheep (Tab. 1). 
Through the introduction or elimination of respective genes, 
a milk was produced with augmented tolerance of high 
temperatures, containing an altered content of casein or a 
decreased content of lactose, representing one of causes of 
alimentary intolerance. An important aspect involved the 
humanization of bovine milk using human proteins and 
reduction of β-lactoglobulin content, the principal allergen 
of milk which induces allergic reactions [7, 28].
An important achievement of biotechnology was the 
production of transgenic mammals, capable of producing 
polyunsaturated fatty acids of the omega-3 and omega-6 
families, highly valued in prophylaxis against certain 
civilization-linked diseases, such as dyslipidaemias, 
arteriosclerosis or arterial hypertension [37]. Transgenic 
animals providing food raw materials point to the novel 
potential of production involving valuable food products. 
Nevertheless, it should be added that the efficiency of genetic 
transformation used to be relatively low and its cost is high, 
while the very process of manipulation within the genomes 
of living organisms has to encounter lack of acceptance on 
the consumer markets [7, 37].
Table 1. Advantageous technological and utilitarian features of 
genetically modified food.
FOOD BENEFITS FROM GENETIC MODIFICATIONS 
Rice
Higher content of β-carotene
Higher iron bioavailability
Tomato
Higher content of dry matter
Delayed ripening process
Aroma intensification
Virus resistance
Potato
Higher amylopectin content
Cyclodextrin production
Resistance to viruses and potato beetle
Lower alkaloids content
Milk
(cow, goat, sheep)
Increased tolerance for high temperature
Modified casein content
Lower lactose content
Transgenic fishes
(carp, salmon, trout)
Faster growth rate
Source: own modifications based on: [7, 19, 22, 33, 37].
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Production of therapeutic substances. The purposefulness of 
genetic modification involving plant raw material, is planned 
to provide therapeutic substances, opening fully novel 
perspectives for pharmacy and medicine. Transgenic varieties 
of potato, salad, tomato and spinach are capable of producing 
the so-called oral vaccines, or substances stimulating the 
human immune system in response to specific pathogens. 
Using genetic engineering techniques, humans have succeeded 
in transferring the genes responsible for expression of viral or 
bacterial antigens directly to plant cell nuclei or chloroplasts. 
The antigens stimulate whole body response which results 
in the production of antibodies, providing stable immunity 
toward selected pathological microflora [22, 36, 38]. It is 
required that the active substances in transgenic vaccines 
are contained in edible portions of vegetables and fruits, and 
that they stimulate mucosal immunity, due to digestion and 
absorption in alimentary tract of humans and/or animals. 
The recommended commercial form of the resistance-
stimulating plants involves a lyophilizate (a freeze-dried 
form), manifesting lowered risk of contamination and more 
favourable storage conditions [3, 21, 36]. The leading examples 
of cultivable edible vaccines are exemplified by varieties of 
rice, maize, soybean or potato, capable of producing antigens 
immunizing against various infections, including the effects 
of Escherichia coli toxins, rabies, infections with Helicobacter 
pylori bacteria, and viral type B hepatitis [3, 22, 24, 38, 39].
Here, it is worth mentioning the achievement of Polish 
scientists who developed a GM salad containing vaccine 
against viral type B hepatitis [36]. However, due to insufficient 
investigative effort, pharmaceuticals produced by transgenic 
plants are still not used on an industrial scale.
The positive effects of the culture and cultivation of 
transgenic organisms are thought to include the potential for 
obtaining recombined proteins, broadly used as a source of 
therapeutic substances. One of trends in plant biotechnology 
involves modification of plant varieties for the purpose 
of synthesis of biologically active compounds, providing 
grounds for the production of drugs, enzymes, antibodies and 
hormones of specific pro-health effects. The most frequent 
objects for such studies are varieties of tobacco, tomato, 
potato, maize, soybean, rice and lucerne. The production 
of biopharmaceutical agents brings about several economic 
advantages, due to their low costs, ease of modification, 
extensive yield and seed production. The recombined proteins 
obtained by the genetic engineering approach include, among 
others, lactoferrin, lysozyme, insulin and insulin-resembling 
growth factor-1 (IGF-1) [22, 36, 38, 40].
An important part of ‘pharming’ (the production of 
therapeutic substances using transgenic organisms) involves 
the use of animals as bioreactors of therapeutic compounds. 
A properly conducted transgenesis includes transformation 
of genes permitting expression of the protein exclusively 
in the target organ of the animal under condition that the 
product is fully innocuous. Very frequently, the therapeutic 
proteins are produced in mammary milk glands. As a result 
of experimental studies, researchers have succeeded in 
obtaining alpha-1-antitrypsin, erythropoetin, plasminogen 
activator, and clotting factors of interferon, produced by 
transgenic goats, sheep or cattle. Production of recombined 
proteins may also take place in the blood or urinary bladder 
of genetically modified animals. In this way, among others, 
human haemoglobin was obtained, manifesting oxygen-
binding activity identical to native haemoglobin. It should be 
mentioned that the breeding of transgenic farm animals is fully 
safe for the environment since such animals cannot propagate 
or survive outside the site devoted to their stay [3, 7, 28, 36, 
39, 41, 42, 43]. Thus, GMO opens an interesting perspective 
for a more economic production of drugs needed by patients.
Potential risks linked to genetically modified food. The 
dissemination of genetically modified food in various 
branches of human activities promoted the introduction 
of detailed controls related to transgenesis products, 
particularly in the scope of evaluating the safety of their 
use, and specification of possible risks associated with the 
consumption of such products [44]. The anxiety of consumers 
is induced both by the effects of genetic modifications, 
including effects of molecular biology techniques which, in 
interfering with the process of natural recombination, disturb 
the ability for normal propagation. The problem of taking 
advantage of transgenic food reflects misgivings of both a 
biological nature, related to the complexity of the involved 
processes, and ethical principles linked to problems of the 
existence of living organisms [20, 45, 46].
Risk of food allergy. The transfer of genes from the cells of one 
organism to the cell nuclei of another organism results in the 
expression and synthesis of new proteins, absent till then in 
parental cells. The amino acid sequence forming structure of a 
given protein poses the main risk of food allergy development 
due to exposure to transgenic food. The term allergy denotes 
a pathological immune reaction, resulting from a response 
to antigen carried by a specific food component. The main 
allergens are thought to involve alimentary proteins, the 
consumption of which may induce sequentially skin reactions, 
alterations in the respiratory system and the circulatory system, 
up to induction of an anaphylactic shock, creating serious 
negative effects for health [7, 20, 47, 48]. Proteins obtained due 
to genetic modifications are thought to carry an allergizing 
potential if its sequence is homologous to another, defined 
allergen, inducing unfavourable immune body reactions. It is 
estimated that food components allergize approximately 2% 
of the world’s adults and as many as 6% of children [7, 47, 49].
Extensive attention is devoted to cases of allergy following 
previous consumption of a transgenic food. The widely 
publicized example of unfavourable GMO effects involved 
the case of Aventis, the American producer of maize given 
the utility name of StarLink. The modified plant contained an 
additional gene, conditioning natural resistance to pesticides. 
The transfer of genetic information from Bacillus thuringiensis 
bacteria to the cell nuclei of maize yielded the expression 
product of Cry9c protein, manifesting strong allergizing 
properties. Due to its specificity, StarLink maize gained the 
acceptance of the Environmental Protection Agency (EPA) 
and was permitted to enter the trade market exclusively as an 
animal fodder. Soon after commercialization of the transgenic 
plant, StarLink maize was detected in food products generally 
accessible on consumer markets (e.g. in tacos). Spread of the 
information through mass media was followed by numerous 
reports by consumers related to symptoms of food allergy 
in the form of headaches, diarrhoeas, nausea and vomiting, 
which were supposed to develop following consumption of 
products containing the genetically modified maize (Tab. 2) 
[7, 45, 47, 50, 51].
Another example of the risk of food allergy development 
involved the production of soybean enriched in methionine, 
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the amino acid obtained by synthesis as a product of the gene 
isolated from a Brazil nut. According to reports of various 
medical organizations, both peanuts and tree-nuts represent 
one of main causes for the development of allergic reactions. 
Therefore, negative health effects following consumption 
of transgenic soybean in humans earlier sensitized to nuts 
represents a serious danger (Tab. 2) [7, 20, 23, 52].
Examples of allergy induced by GM food are most 
frequently related to varieties equipped with new expression 
genes, originating from organisms with a specific allergizing 
potential. In the case of lupine and lucerne, the introduction of 
genetic material originating from seeds of sunflower resulted 
in the appearance of allergy resembling that developing after 
the consumption of Brazil nuts [52].
Synthesis of toxic compounds. A significant problem linked 
to the effects of GMO to consumers’ health and life is the 
potential for synthesis in their cells and tissues of anti-
alimentary, toxic products or products which increase risk 
of activating neoplastic processes. This can be exemplified by 
events which took place in Spain in 1983, when a modified 
rape oil with a pronounced toxic effect was permitted to 
enter the general market. Despite earlier results obtained 
on rats, which failed to demonstrate any disturbances in 
physiology, consumption of the oil resulted in the deaths 
of a marked number of the consumers. This tragedy caused 
various investigatory centres to undertake efforts to explain 
the phenomenon. It was speculated that the intoxication 
induced the so-called toxic oil syndrome (TOS), reflecting 
contamination of the oil with aniline or its derivatives, 
responsible for the toxic signs. Experiments by Suarez et al. 
conducted on rats fed for 2 months with oil contaminated with 
oleoylanilide, failed to demonstrate significant differences 
with rats of a control group which received food with pure 
oil, although the situation might have reflected an insufficient 
supply of the supposedly toxic agent. Other studies performed 
by Quero et al., pointed to the possibility of genetic diversity 
in response to TOS [7, 53, 54]. Potentially toxic effects of 
transgenic food were also recorded in the United States in 
1989, when transgenic tryptophan caused death and pain 
(mainly in muscles and joints) in many people. The compound, 
distributed by a Japanese producer, was produced by genetically 
modified bacteria, altered with respect to production efficacy. 
The L-tryptophan, playing the role of a food supplement 
and used for the treatment of, among others, insomnia or 
depression, induced undesirable body reactions in the form 
of eosinophilia-myalgia syndrome (EMS). The causes of the 
intoxication are thought to be associated, first of all, with 
altered production technology and altered purification of the 
compound, which took place just in 1989 [4, 7, 9].
The risk of an increased morbidity to tumours resulting 
from the consumption of GM food seems to be equally 
alarming. In 2002, results were published which demonstrated 
that milk from genetically modified cows increases levels of 
IGF-1 factor in consumers, showing a positive correlation 
with development of tumours in lungs, breast and colon. 
Experiments are being conducted to evaluate links between 
cultivable plants rendered resistant to pesticides with the 
frequency of  lymphoma development in humans and animals 
consuming products resulting from the transformation of 
such plants (Tab. 2) [7, 9].
The relationships of transgenic food effects on human 
body are being investigated by conducting numerous tests 
on animals. Thus, a few independently working groups of 
researchers have presented data on the potentially harmful 
influences of MON810 maize (resistant to corn borer) on cells 
of the pancreas, intestines, liver and kidneys in rodents (Tab. 2) 
[44]. Results of other studies testing the effects of different 
varieties of transgenic maize (MON810 and MON863) on living 
bodies – the maize producing Bt toxin making it resistant to 
insects, and NK603, maize, resistant to the Roundup herbicide 
– pointed to the potential for induction of histopathological 
lesions first of all in liver and kidneys and, thus, in the principal 
detoxifying organs. This was confirmed by experiments on rats 
fed for 90 days with 11% or 33%, respectively, of components 
of transgenic maize, and compared to a control group of rats 
fed the unmodified analogue. However, attention was drawn 
to the fact that the low number of rats (80) which consumed 
the genetically modified maize, compared to the number of 
rats consuming the non-transgenic equivalents (a four-fold 
higher group numerically). Moreover, the chronic toxic effects 
should be evaluated after long-term monitoring – for a period 
of about two years – while the quoted studies lasted for only 
three months [55, 56].
In order to define the health effects of chronic alimentation 
with transgenic products a group of rats was studies, fed with 
various doses of NK603 modified maize, grown with or in 
absence of exposure to Roundup herbicide, using food free 
of GMO but containing water with the addition of varying 
amounts of Roundup, or using food free of GMO or the 
herbicide (control). The results of the two-year experiment 
suggested manifestation of disturbances in the function 
of liver and kidneys, a higher mortality of animals, and 
manifestation of palpable tumours in the experimental groups 
(particularly those exposed to Roundup), compared to the 
control. Female rats manifested an increased sensitivity to the 
food containing toxic compounds. It was suggested that this 
was linked to, among others, a lowered content of isoflavonoid 
antioxidants: ferulic acid, reduced by 16–30% and caffeic 
acid, reduced by 21–53% in NK603 maize, which reflected 
an overexpression of 5-enolpyruvylshikimate-3-phosphate 
synthase (EPSP) gene, originating from Agrobacterium 
tumefaciens – and permitting the plant to be resistant to 
Roundup [57]. A modulating effect of the above-mentioned 
isoflavonoids was demonstrated on estrogen receptors and, 
therefore, their chemopreventive and anti-inflammatory 
effects [57, 58].
The analyses by Pusztai are also worth attention. He 
detected that lectin, the agglutinin synthesised by GM 
potatoes, was toxic for the growth and development of 
mammals. A diet consisting of genetically modified potatoes 
containing a lectin, synthetized as a product of the expression 
of a gene selected from Galanthus nivalis, negatively affected 
the alimentary tract in rodents [4, 23, 45]. Following exposure 
of rats to the diet, the unfavourable effects were identified, 
which included disturbed cell division, particularly in the 
gastric mucosa. The arising abnormalities were suggested to 
be linked not only with the presence of the transgene, but also 
with other elements of the genetic construction, and with the 
process of transformation of genetic information. It should 
also be added that the described experiments involved small 
numbers of animals, and the duration of studies reached just 
10 days (Tab. 2) [4, 45, 50, 59]. In quoting the above data, it 
becomes indispensable to mention the need for a detailed 
examination of transgenic food before it is introduced into 
the food markets.
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The practical use of genetic engineering techniques allows 
the formation of organisms with new traits, which in favourable 
conditions may pass from laboratories and food factories 
to environment. The uncontrollable spread of GM plants 
induces anxiety among ecologists due to the risk of a disturbed 
biological equilibrium in ecosystems. Toxins produced by 
modified plants and secreted throughout their vegetation 
period, may manifest ability to become accumulated in 
individual organs of the plants, and may cause some pests to 
become resistant to the harmful substance. In effect, instead of 
a reduction in the required doses of insecticides, it may prove 
necessary to increase the doses of pesticides, thus nullifying 
the effect of the conducted manipulations [7, 9, 10, 60].
A similar problem is posed by the fear of development of 
‘super weeds’ resistant to herbicides. An assumption of the 
performed transgenesis process was that the introduced 
new gene will provide the plant with protection against 
herbicides. Following such a procedure, only a single type 
of herbicide could be used in small doses. However, through 
the unwanted hybridization of transgenic plants with weeds, 
one cannot exclude the formation of new species, insensitive 
to the herbicides targeted at them. Moreover, the new plants 
resistant to anti-weed agents will require the use of higher 
amounts of herbicide to destroy them, which results in 
contamination of water and soil and which may negatively 
affect the health of consumers [7, 20, 21, 44].
Development of resistance to antibiotics. A subsequent 
significant aspect posed by the opponents of GMO involves 
the risk of development of resistance to antibiotics, 
understood as a risk of transferring genes of resistance to 
antibiotics to genetically modified organisms. At the early 
stage of the transgenesis process, bacteria are frequently used, 
similar to bacterial genes resistant to therapeutic antibiotics, 
playing in parallel the role of markers or elements allowing to 
distinguish transformed cells from cells which did not accept 
the coding alleles. The common application of therapeutic 
agents as modifying agents poses the danger of transferring 
genes of resistance to the bacterial microflora of human 
and animal alimentary tracts – both the physiological and 
pathogenic microflora. In consequence, pathogens inducing 
various diseases may develop a stable lack of sensitivity to 
specific antibiotics, with resulting lowered efficacy or total 
loss of effectiveness of respective treatment. Thus, in order to 
avoid negative health effects, avoidance of using antibiotics as 
markers is recommended [7, 9, 44, 49, 61]. In order to avoid 
the negative health effects, avoidance is also recommended 
of using antibiotics as markers to the advantage of specific 
marker genes, such as nptII, which pose no risk to humans 
or animals [62].
SUMMARY
The study presents possible directions in which genetic 
modifications can be used, stressing the advantages and 
risks resulting from the consumption of transgenic food. 
The respective cultivation and production of modified 
products involve lower production costs and provide higher 
nutritive value of the obtained food products. The advantages 
resulting from the use of GMO result in increased profit 
for producers, provide therapeutic products, and increased 
variability of the obtained products and products with 
desirable organoleptic and utility traits [7, 21, 34, 46, 63]. 
Safety in the use of genetically modified food became higher 
due to incessant monitoring and testing GMO, required for 
admission to the trade market, even if GMO forms only a 
component of food [19, 20, 29]. Consumption of genetically 
modified food entails risk of undesirable effects, similar to 
the consumption of traditional food. The difference is in 
the fact of forming new experimental arrangements and 
the relatively short duration of using transgenesis products. 
The main apprehension of GMO opponents is focused on 
the health of consumers. It is speculated that genetically 
modified food is responsible for the development of food 
allergies, resistance to antibiotics and synthesis of toxic 
substances. The appearance of risks associated with a broad 
use of GMO provides the basis for criticism from the side 
of biotechnology opponents. However, to date, it has not 
been clarified if the harmful effects result from products 
of genetic modifications or from the transgenesis process, 
affected by, among others, circumstances of the conducted 
manipulations [7, 20, 28, 46]. To date, no completely negative 
effects of transgenic food on the human body or its complete 
harmlessness could have been documented. Increasing 
amounts of GMO-containing assortments are introduced 
to the trade market and the consumers themselves must 
decide whether or not to consume transgenic food, which 
should be appropriately labelled and supplied with reliable 
information on the conducted modifications [13, 28, 63].
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